Condition: Locally Advanced (Unresectable) or Metastatic Solid Tumors · Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.
This study was an open-label phase Ⅱ study to evaluate the safety and efficacy of SSGJ-705 Plus SSGJ-612 ± Chemotherapy in patients with advanced HER2-Expressing Solid Tumors.
This description comes directly from the study's public registry record.
Jieer Ying, M.D. · +86-13858195803 · hzyingjieer@163.com
Meifang Zheng, M.D. · +86-15258894828 · 794998553@qq.com
Always discuss trial participation with your own doctor first.
| Zhejiang Cancer Hospital | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07646626